Thiophene pyrazolopyrimidine compounds
The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
1. A compound of Formula I
wherein:
R 1 and R 2 are independently hydrogen or C 1 -C 3 alkyl;
R 3 is
R 4 is Cl or methyl;
R 5 is
or a pharmaceutically acceptable salts thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently ethyl or n-propyl.
3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. The compound of claim 1 which is 3-[3-Chloro-5-(2-methyl-2H-[1,2,4]triazole-3-yl)-thiophene-2-yl]-7-(1-propyl-butyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine, or a pharmaceutically acceptable salt thereof.